secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2026-05-14T20:42:13+00:00
Accession:  0001193125-26-224214
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Q1 net loss $22.1M; FB102 gets FDA Fast Track; raised $172.5M in April
----------------------------------------------------------------------------

- Q1 2026 net loss $22.1M ($1.24 per share); cash $58.2M at March 31, 2026.
- FB102 received FDA Fast Track Designation for celiac disease; phase 2 topline results expected in 2026.
- Phase 1b vitiligo data expected shortly; alopecia areata data readout in 2026.
- R&D expenses rose to $20.5M from $12.7M YoY due to increased clinical and preclinical costs.
- In April 2026, raised $172.5M gross via equity offering, issuing 6.6M common shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312526224214/0001193125-26-224214-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312526224214/d95486d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-224214

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer